|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
|
2
|
Matsuda A and Machii R: Trends in stomach
cancer mortality rates in Japan, USA, UK, France and Korea based on
the WHO mortality database. Jpn J Clin Oncol. 42:1542012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zheng LH, Bao YL, Wu Y, Yu CL, Meng X and
Li YX: Cantharidin reverses multidrug resistance of human hepatoma
HepG2/ADM cells via down-regulation of P-glycoprotein expression.
Cancer Lett. 272:102–109. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Volm M and Mattern J: Resistance
mechanisms and their regulation in lung cancer. Crit Rev Oncog.
7:227–244. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mervis J: Ancient remedy performs new
tricks. Science. 273:5781996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhu J, Chen Z, Lallemand-Breitenbach V and
de Thé H: How acute promyelocytic leukaemia revived arsenic. Nat
Rev Cancer. 2:705–713. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang TD, Chen GQ, Wang ZG, Wang ZY, Chen
SJ and Chen Z: Arsenic trioxide, a therapeutic agent for APL.
Oncogene. 20:7146–7153. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lo-Coco F, Avvisati G, Vignetti M, Thiede
C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona
E, et al: Retinoic acid and arsenic trioxide for acute
promyelocytic leukemia. N Engl J Med. 369:111–121. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Murgo AJ: Clinical trials of arsenic
trioxide in hematologic and solid tumors: Overview of the National
Cancer Institute Cooperative Research and Development Studies.
Oncologist. 6(Suppl 2): 22–28. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lu J, Chew EH and Holmgren A: Targeting
thioredoxin reductase is a basis for cancer therapy by arsenic
trioxide. Proc Natl Acad Sci USA. 104:12288–12293. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Munshi NC: Arsenic trioxide: An emerging
therapy for multiple myeloma. Oncologist. (6 Suppl 2): 17–21. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Maeda H, Hori S, Nishitoh H, Ichijo H,
Ogawa O, Kakehi Y and Kakizuka A: Tumor growth inhibition by
arsenic trioxide (As2O3) in the orthotopic metastasis model of
androgen-independent prostate cancer. Cancer Res. 61:5432–5440.
2001.PubMed/NCBI
|
|
14
|
Shen ZY, Zhang Y, Chen JY, Chen MH, Shen
J, Luo WH and Zeng Y: Intratumoral injection of arsenic to enhance
antitumor efficacy in human esophageal carcinoma cell xenografts.
Oncol Rep. 11:155–159. 2004.
|
|
15
|
Bornstein J, Sagi S, Haj A, Harroch J and
Fares F: Arsenic Trioxide inhibits the growth of human ovarian
carcinoma cell line. Gynecol Oncol. 99:726–729. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Woo SH, Park IC, Park MJ, Lee HC, Lee SJ,
Chun YJ, Lee SH, Hong SI and Rhee CH: Arsenic trioxide induces
apoptosis through a reactive oxygen species-dependent pathway and
loss of mitochondrial membrane potential in HeLa cells. Int J
Oncol. 21:57–63. 2002.PubMed/NCBI
|
|
17
|
Miller WH Jr, Schipper HM, Lee JS, Singer
J and Waxman S: Mechanisms of action of arsenic trioxide. Cancer
Res. 62:3893–3903. 2002.PubMed/NCBI
|
|
18
|
Pelicano H, Feng L, Zhou Y, Carew JS,
Hileman EO, Plunkett W, Keating MJ and Huang P: Inhibition of
mitochondrial respiration: a novel strategy to enhance drug-induced
apoptosis in human leukemia cells by a reactive oxygen
species-mediated mechanism. J Biol Chem. 278:37832–37839. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Eguchi R, Fujimori Y, Takeda H, Tabata C,
Ohta T, Kuribayashi K, Fukuoka K and Nakano T: Arsenic trioxide
induces apoptosis through JNK and ERK in human mesothelioma cells.
J Cell Physiol. 226:762–768. 2011. View Article : Google Scholar
|
|
20
|
Xia J, Li Y, Yang Q, Mei C, Chen Z, Bao B,
Ahmad A, Miele L, Sarkar FH and Wang Z: Arsenic trioxide inhibits
cell growth and induces apoptosis through inactivation of notch
signaling pathway in breast cancer. Int J Mol Sci. 13:9627–9641.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xiao Z, Ding N, Xiao G, Wang S, Wu Y and
Tang L: Reversal of multidrug resistance by gefitinib via RAF1/ERK
pathway in pancreatic cancer cell line. Anat Rec (Hoboken).
295:2122–2128. 2012. View Article : Google Scholar
|
|
22
|
Zhao D, Jiang Y, Dong X, Liu Z, Qu B,
Zhang Y, Ma N and Han Q: Arsenic trioxide reduces drug resistance
to adriamycin in leukemic K562/A02 cells via multiple mechanisms.
Biomed Pharmacother. 65:354–358. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao Y, You H, Liu F, An H, Shi Y, Yu Q
and Fan D: Differentially expressed gene profiles between multidrug
resistant gastric adenocarcinoma cells and their parental cells.
Cancer Lett. 185:211–218. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Che XF, Nakajima Y, Sumizawa T, Ikeda R,
Ren XQ, Zheng CL, Mukai M, Furukawa T, Haraguchi M, Gao H, et al:
Reversal of P-glycoprotein mediated multidrug resistance by a newly
synthesized 1,4-benzothiazipine derivative, JTV-519. Cancer Lett.
187:111–119. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang R, Xia L, Gabrilove J, Waxman S and
Jing Y: Downregulation of Mcl-1 through GSK-3β activation
contributes to arsenic trioxide-induced apoptosis in acute myeloid
leukemia cells. Leukemia. 27:315–324. 2013. View Article : Google Scholar
|
|
26
|
Brandstetter T, Ninci E, Falken U, Wagner
E, Hess R and Bauknecht T: rhG-CSF affects genes involved in
mitogen signalling and early gene expression in the ovarian cancer
cell line HEY. Int J Cancer. 75:847–854. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ricciardi MR, McQueen T, Chism D, Milella
M, Estey E, Kaldjian E, Sebolt-Leopold J, Konopleva M and Andreeff
M: Quantitative single cell determination of ERK phosphorylation
and regulation in relapsed and refractory primary acute myeloid
leukemia. Leukemia. 19:1543–1549. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Newman MJ, Rodarte JC, Benbatoul KD,
Romano SJ, Zhang C, Krane S, Moran EJ, Uyeda RT, Dixon R, Guns ES,
et al: Discovery and characterization of OC144-093, a novel
inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer
Res. 60:2964–2972. 2000.PubMed/NCBI
|
|
29
|
Li Y, Qu X, Qu J, Zhang Y, Liu J, Teng Y,
Hu X, Hou K and Liu Y: Arsenic trioxide induces apoptosis and G2/M
phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and
thereby regulate p53 activation. Cancer Lett. 284:208–215. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen X, Zhang M and Liu LX: The
overexpression of multidrug resistance-associated proteins and
gankyrin contribute to arsenic trioxide resistance in liver and
gastric cancer cells. Oncol Rep. 22:73–80. 2009.PubMed/NCBI
|
|
31
|
Liu Y, Zhang W, Zhang X, Qi Y, Huang D and
Zhang Y: Arsenic trioxide inhibits invasion/migration in SGC-7901
cells by activating the reactive oxygen species-dependent
cyclo-oxygenase-2/matrix metalloproteinase-2 pathway. Exp Biol Med
(Maywood). 236:592–597. 2011. View Article : Google Scholar
|
|
32
|
Zhang G, Liu J, Zhang Y, Qu J, Xu L, Zheng
H, Liu Y and Qu X: Cbl-b-dependent degradation of FLIP(L) is
involved in ATO-induced autophagy in leukemic K562 and gastric
cancer cells. FEBS Lett. 586:3104–3110. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Baguley BC: Multiple drug resistance
mechanisms in cancer. Mol Biotechnol. 46:308–316. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gillet JP and Gottesman MM: Mechanisms of
multidrug resistance in cancer. Methods Mol Biol. 596:47–76. 2010.
View Article : Google Scholar
|
|
35
|
Wong KA, Russo A, Wang X, Chen YJ, Lavie A
and O'Bryan JP: A new dimension to Ras function: A novel role for
nucleotide-free Ras in Class II phosphatidylinositol 3-kinase beta
(PI3KC2β) regulation. PLoS One. 7:e453602012. View Article : Google Scholar
|
|
36
|
Karnoub AE and Weinberg RA: Ras oncogenes:
Split personalities. Nat Rev Mol Cell Biol. 9:517–531. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kindler HL, Aklilu M, Nattam S and Vokes
EE: Arsenic trioxide in patients with adenocarcinoma of the
pancreas refractory to gemcitabine: A phase II trial of the
University of Chicago Phase II Consortium. Am J Clin Oncol.
31:553–556. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
NCCN Clinical Practice Guidelines in
Oncology (NCCN Guidelines)Gastric Cancer. 3rd edition. National
Comprehensive Cancer Network; Fort Washington: 2015
|
|
39
|
Guo H, Sun F, Huang W, Liu Z, Zhang S,
Zhou Q and Liang C: The effect of rhG-CSF on spleen transcriptome
in mouse leukopenia model induced by cyclophosphamide.
Immunopharmacol Immunotoxicol. 36:114–123. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kumar J, Fraser FW, Riley C, Ahmed N,
McCulloch DR and Ward AC: Granulocyte colony-stimulating factor
receptor signalling via Janus kinase 2/signal transducer and
activator of transcription 3 in ovarian cancer. Br J Cancer.
110:133–145. 2014. View Article : Google Scholar :
|
